Phase I study of the safety and pharmacokinetics of epitinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced solid tumors

被引：0
|
作者：
Zhou, Qing
Wu, Yi Long
Yu, Xiyong
Yang, Jinji
Wen, Limin
Sai, Yang
Mu, Hua
机构：
[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Guangdong Gen Hosp, Med Res Ctr, Guangzhou, Guangdong, Peoples R China
[4] Hutchison MediPharma, Shanghai, Peoples R China
[5] Hutchison Medi Pharma, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19042
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
    Okamoto, Isamu
    Kaneda, Hiroyasu
    Satoh, Taroh
    Okamoto, Wataru
    Miyazaki, Masaki
    Morinaga, Ryotaro
    Ueda, Shinya
    Terashima, Masaaki
    Tsuya, Asuka
    Sarashina, Akiko
    Konishi, Koichi
    Arao, Tokuzo
    Nishio, Kazuto
    Kaiser, Rolf
    Nakagawa, Kazuhiko
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (10) : 2825 - 2833
  • [2] Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors
    Zhao, Qiong
    Shentu, Jianzhong
    Xu, Nong
    Zhou, Jianya
    Yang, Guangdie
    Yao, Yinan
    Tan, Fenlai
    Liu, Dongyang
    Wang, Yingxiang
    Zhou, Jianying
    LUNG CANCER, 2011, 73 (02) : 195 - 202
  • [3] A phase I study of the VEGF/PDGF receptor tyrosine kinase inhibitor AG-013736 in patients with advanced solid tumors: Safety, pharmacokinetics, and dceMRI.
    Herbst, R
    Rugo, H
    Liu, G
    Park, J
    Kies, M
    Pithavala, Y
    McShane, T
    Evelhoch, J
    Steinfeldt, H
    Reich, S
    Freddo, J
    Wilding, G
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6265S - 6265S
  • [4] Phase I study of BMS-599626, an oral pan-HER tyrosine kinase inhibitor, in patients with advanced solid tumors
    Garland, LL
    Pegram, M
    Song, S
    Mendelson, D
    Parker, KE
    Martell, RE
    Gordon, MS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 229S - 229S
  • [5] Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics
    Macarulla, Teresa
    Cervantes, Andres
    Elez, Elena
    Rodriguez-Braun, Edith
    Baselga, Jose
    Rosello, Susana
    Sala, Gemma
    Blasco, Inma
    Danaee, Hadi
    Lee, Yih
    Ecsedy, Jeffrey
    Shinde, Vaishali
    Chakravarty, Arijit
    Bowman, Douglas
    Liu, Hua
    Eton, Omar
    Fingert, Howard
    Tabernero, Josep
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (10) : 2844 - 2852
  • [6] Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
    Sun, Yongkun
    Niu, Wei
    Du, Feng
    Du, Chunxia
    Li, Shuting
    Wang, Jinwan
    Li, Li
    Wang, Fengqing
    Hao, Yu
    Li, Chuan
    Chi, Yihebali
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9 : 1 - 9
  • [7] Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
    Yongkun Sun
    Wei Niu
    Feng Du
    Chunxia Du
    Shuting Li
    Jinwan Wang
    Li Li
    Fengqing Wang
    Yu Hao
    Chuan Li
    Yihebali Chi
    Journal of Hematology & Oncology, 9
  • [8] Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors
    Daud, Adil I.
    Krishnamurthi, Smitha S.
    Saleh, Mansoor N.
    Gitlitz, Barbara J.
    Borad, Mitesh J.
    Gold, Philip J.
    Chiorean, Elena G.
    Springett, Gregory M.
    Abbas, Richat
    Agarwal, Shefali
    Bardy-Bouxin, Nathalie
    Hsyu, Poe-Hirr
    Leip, Eric
    Turnbull, Kathleen
    Zacharchuk, Charles
    Messersmith, Wells A.
    CLINICAL CANCER RESEARCH, 2012, 18 (04) : 1092 - 1100
  • [9] Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors
    Eckhardt, SG
    Rizzo, J
    Sweeney, KR
    Cropp, G
    Baker, SD
    Kraynak, MA
    Kuhn, JG
    Villalona-Calero, MA
    Hammond, L
    Weiss, G
    Thurman, A
    Smith, L
    Drengler, R
    Eckardt, JR
    Moczygemba, J
    Hannah, AL
    Von Hoff, DD
    Rowinsky, EK
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1095 - 1104
  • [10] Phase I study of safety, tolerability, and pharmacokinetics of pazopanib in combination with oral topotecan in patients with advanced solid tumors
    Kerklaan, Bojana Milojkovic
    Lolkema, Martijn P. J. K.
    Devriese, Lot A.
    Voest, Emile E.
    Nol-Boekel, A.
    Mergui-Roelvink, M.
    Mykulowycz, Kristine
    Stoebenau, Joseph E.
    Fang, Lei
    Legenne, Philippe
    Wissel, Paul Stephen
    Smith, Deborah A.
    Giantonio, Bruce J.
    Schellens, Jan H. M.
    Witteveen, Petronella
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345